Ayala Pharmaceuticals Inc. (ADXS)

OTCMKTS: ADXS · Delayed Price · USD
0.841
-0.071 (-7.74%)
Mar 4, 2024, 3:02 PM EST - Market closed
Market Cap 35.79M
Revenue (ttm) 263,000
Net Income (ttm) -28.36M
Shares Out 42.63M
EPS (ttm) -7.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,305
Open 0.861
Previous Close 0.911
Day's Range 0.841 - 0.891
52-Week Range 0.504 - 1.950
Beta n/a
Analysts Hold
Price Target n/a
Earnings Date Sep 11, 2023

About ADXS

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 14
Stock Exchange OTCMKTS
Ticker Symbol ADXS
Full Company Profile

Financial Performance

In 2022, ADXS's revenue was $250,000, a decrease of -92.28% compared to the previous year's $3.24 million. Losses were -$14.36 million, -19.61% less than in 2021.

Financial Statements

News

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announc...

Other symbols: IMNM
13 days ago - Business Wire

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

BOTHELL, Wash. & MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to...

Other symbols: IMNM
27 days ago - Business Wire

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population   AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T...

4 months ago - GlobeNewsWire

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger wit...

4 months ago - GlobeNewsWire

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Defin...

7 months ago - GlobeNewsWire

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it wil...

7 months ago - GlobeNewsWire

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala's portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, Isra...

7 months ago - GlobeNewsWire

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily

8 months ago - GlobeNewsWire

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose)

10 months ago - GlobeNewsWire

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial...

10 months ago - GlobeNewsWire

Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee

Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally

1 year ago - GlobeNewsWire

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clini...

1 year ago - GlobeNewsWire

Advaxis and Ayala Pharmaceuticals Complete Merger

REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and comme...

1 year ago - GlobeNewsWire

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University

1 year ago - GlobeNewsWire

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

Merger brings U.S. management and presence, cash to develop compelling late-stage asset

1 year ago - GlobeNewsWire

Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer

1 year ago - GlobeNewsWire

Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

Announced Publication of ADXS-PSA Data in The Oncologist

1 year ago - GlobeNewsWire

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immun...

1 year ago - GlobeNewsWire

Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® (pe...

1 year ago - GlobeNewsWire

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy produc...

2 years ago - GlobeNewsWire

Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

ADXS-PSA in combination with KEYTRUDA ® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visce...

2 years ago - GlobeNewsWire

ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS

NEW YORK--(BUSINESS WIRE)--Kahn Swick & Foti, LLC and Monteverde & Associates PC announce that, on March 28, 2022, Advaxis, Inc. issued a Supplemental Proxy Statement that includes additional clarifyi...

2 years ago - Business Wire

Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update

Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

2 years ago - GlobeNewsWire

Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update

MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy product...

2 years ago - GlobeNewsWire

Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy product...

2 years ago - GlobeNewsWire